Sylvie D Lambert1,2, Lindsay R Duncan3, Janet Ellis4,5, John Wellesley Robinson6,7, Carly Sears8, Nicole Culos-Reed9,10,11, Andrew Matthew12,4,13, Manon De Raad14, Jamie Lynn Schaffler14, Daniel Santa Mina15,16, Paramita Saha-Chaudhuri17, Helen McTaggart-Cowan18,19, Stuart Peacock18,19,20. 1. Ingram School of Nursing, McGill University, Montreal, Quebec, Canada. sylvie.lambert@mcgill.ca. 2. St. Mary's Research Centre, Montreal, Quebec, Canada. sylvie.lambert@mcgill.ca. 3. Department of Kinesiology and Physical Education, McGill University, Montreal, Quebec, Canada. 4. Department of Psychiatry, University of Toronto, Toronto, Canada. 5. Psychosocial Care in Trauma, Sunnybrook Health Sciences Centre, Toronto, Canada. 6. Department of Psychology, University of Calgary, Calgary, Canada. 7. Department of Oncology, University of Calgary, Calgary, Canada. 8. University of Calgary, Calgary, Canada. 9. Health and Exercise Psychology, Faculty of Kinesiology, University of Calgary, Calgary, Canada. 10. Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada. 11. Psychosocial Resources, Tom Baker Cancer Centre, Cancer Care, Alberta Health Services, Edmonton, Canada. 12. Faculty of Medicine, Department of Surgery, University of Toronto, Toronto, Canada. 13. Department of Surgery, Princess Margaret Cancer Centre, Toronto, Canada. 14. St. Mary's Research Centre, Montreal, Quebec, Canada. 15. Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, Canada. 16. Toronto General Hospital, Toronto, Canada. 17. Department of Mathematics and Statistics, University of Vermont, Burlington, VT, USA. 18. Canadian Centre for Applied Research in Cancer Control, Toronto, Canada. 19. Cancer Control Research, BC Cancer, Vancouver, Canada. 20. Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
Abstract
BACKGROUND:Prostate cancer predisposes patients and caregivers to a wide range of complex physical and psychosocial challenges, and interventions must incorporate a wide range of self-management strategies to help patients and their caregivers effectively cope with cancer challenges. To palliate this need, our team recently developed and evaluated the initial acceptability of a dyadic, Tailored, wEb-based, psychosocial, and physical activity self-Management PrOgram (TEMPO). TEMPO is a 10-week, interactive, web-based intervention consisting of five modules designed to help dyads manage their physical and psychosocial needs. It aims to teach dyads new self-management strategies and encourages them to increase their physical activity (PA) levels, mainly through walking and strength-based exercises. Initial acceptability evaluation of TEMPO revealed high user satisfaction, in addition to having a number of potential benefits for participants. After integrating suggested changes to TEMPO, the proposed pilot study aims to further test the acceptability and feasibility of TEMPO. METHODS: This study is a multicenter, stratified, parallel, two-group, pilot randomized control trial (RCT), where patient-caregiver dyads are randomized (stratified by anxiety level) to receive (a) TEMPO or (b) usual care. Participants (n goal = 40) are recruited across Canada at participating cancer centers and through self-referral (e.g., online recruitment). Patient inclusion criteria are (a) having received prostate cancer treatment within the past 2 years or scheduled to receive treatment, (b) identified a primary caregiver willing to participate in the study, and (c) has access to the Internet. Eligible caregivers are those identified by the patient as his primary source of support. Dyads complete a baseline questionnaire (T1) and another one 3 months later (T2) assessing various aspects of physical and emotional functioning (e.g., the Medical Outcomes Study (MOS) 12-item Short Form Health Survey (SF-12), the Hospital Anxiety and Depression Scale (HADS), and the Perceived Stress Scale (PSS)), self-management behaviors (e.g., the Health Education Impact Questionnaire (heiQ)), physical activity (the International Physical Activity Questionnaires (IPAQ) and the Multidimensional Self-efficacy for Exercise Scale (MSES)), and dyadic coping (the Dyadic Coping Inventory (DCI)). Dyads that used TEMPO are also asked to participate in a semi-structured exit interview exploring their overall experience with the program. DISCUSSION: This feasibility analysis will begin to develop the knowledge base on TEMPO's value for men with prostate cancer and their caregivers to inform a larger trial. TRIAL REGISTRATION: NCT04304196.
RCT Entities:
BACKGROUND:Prostate cancer predisposes patients and caregivers to a wide range of complex physical and psychosocial challenges, and interventions must incorporate a wide range of self-management strategies to help patients and their caregivers effectively cope with cancer challenges. To palliate this need, our team recently developed and evaluated the initial acceptability of a dyadic, Tailored, wEb-based, psychosocial, and physical activity self-Management PrOgram (TEMPO). TEMPO is a 10-week, interactive, web-based intervention consisting of five modules designed to help dyads manage their physical and psychosocial needs. It aims to teach dyads new self-management strategies and encourages them to increase their physical activity (PA) levels, mainly through walking and strength-based exercises. Initial acceptability evaluation of TEMPO revealed high user satisfaction, in addition to having a number of potential benefits for participants. After integrating suggested changes to TEMPO, the proposed pilot study aims to further test the acceptability and feasibility of TEMPO. METHODS: This study is a multicenter, stratified, parallel, two-group, pilot randomized control trial (RCT), where patient-caregiver dyads are randomized (stratified by anxiety level) to receive (a) TEMPO or (b) usual care. Participants (n goal = 40) are recruited across Canada at participating cancer centers and through self-referral (e.g., online recruitment). Patient inclusion criteria are (a) having received prostate cancer treatment within the past 2 years or scheduled to receive treatment, (b) identified a primary caregiver willing to participate in the study, and (c) has access to the Internet. Eligible caregivers are those identified by the patient as his primary source of support. Dyads complete a baseline questionnaire (T1) and another one 3 months later (T2) assessing various aspects of physical and emotional functioning (e.g., the Medical Outcomes Study (MOS) 12-item Short Form Health Survey (SF-12), the Hospital Anxiety and Depression Scale (HADS), and the Perceived Stress Scale (PSS)), self-management behaviors (e.g., the Health Education Impact Questionnaire (heiQ)), physical activity (the International Physical Activity Questionnaires (IPAQ) and the Multidimensional Self-efficacy for Exercise Scale (MSES)), and dyadic coping (the Dyadic Coping Inventory (DCI)). Dyads that used TEMPO are also asked to participate in a semi-structured exit interview exploring their overall experience with the program. DISCUSSION: This feasibility analysis will begin to develop the knowledge base on TEMPO's value for men with prostate cancer and their caregivers to inform a larger trial. TRIAL REGISTRATION: NCT04304196.
Entities:
Keywords:
Cancer rehabilitation; Cancer survivorship; Caregivers; Dyadic intervention; Prostate cancer; Self-management
Authors: Sylvie D Lambert; Lindsay R Duncan; Sophia Kapellas; Anne-Marie Bruson; Melanie Myrand; Daniel Santa Mina; Nicole Culos-Reed; Angella Lambrou Journal: Ann Behav Med Date: 2016-12
Authors: Sylvie D Lambert; Afaf Girgis; Jane Turner; Tim Regan; Hayley Candler; Ben Britton; Suzanne Chambers; Catalina Lawsin; Karen Kayser Journal: Support Care Cancer Date: 2013-08-17 Impact factor: 3.603
Authors: Sylvie D Lambert; Lindsay R Duncan; S Nicole Culos-Reed; Laura Hallward; Celestia S Higano; Ekaterina Loban; Anne Katz; Manon De Raad; Janet Ellis; Melissa B Korman; Carly Sears; Cindy Ibberson; Lauren Walker; Eric Belzile; Paramita Saha-Chaudhuri; Helen McTaggart-Cowan; Stuart Peacock Journal: Curr Oncol Date: 2022-02-01 Impact factor: 3.677